Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-17-002467
Filing Date
2017-03-16
Accepted
2017-03-16 16:35:30
Documents
1
Period of Report
2017-03-14

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT f4031417traversa_actinium.html 4  
1 OWNERSHIP DOCUMENT f4031417traversa_actinium.xml 4 3936
  Complete submission text file 0001213900-17-002467.txt   5382
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 138 CANTERBURY LN BLUE BELL PA 19422
Business Address
TRAVERSA SERGIO (Reporting) CIK: 0001565832 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36374 | Film No.: 17694991